Flexion Therapeutics Names Arthur Fratamico Chief Business Officer
WOBURN, Mass., June 19, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced that Arthur J. Fratamico, R.Ph., has joined the company as its first chief business officer. He has more than 13 years of business development experience with emerging biopharmaceutical companies.
Prior to joining Flexion, Mr. Fratamico, 46, led the business development efforts for Trevena, Gemin X Pharmaceuticals and MGI PHARMA. While at MGI PHARMA, Mr. Fratamico led the corporate development group which oversaw numerous licensing transactions and acquisitions including that of Aesgen, Akarx, Guilford and Zycos ultimately culminating in the sale of MGI PHARMA to Eisai. While at Gemin X, Mr. Fratamico closed the sale of that company to Cephalon for $525 million.
"We are delighted to have someone of Art's experience and capability join our executive team, particularly at this exciting time for the company," said Michael Clayman, M.D., chief executive officer of Flexion. "Our recently announced positive Phase 2 data for FX005 has accelerated interest from potential partners and Art will play a key role advancing these discussions."
Fratamico holds a bachelor's degree in Pharmacy from Philadelphia College of Pharmacy and Science and a master's in business administration with a dual concentration in marketing and finance from Drexel University.
About Flexion Therapeutics
Flexion discovers and develops innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety, we are merging novel pharmacology with local, sustained delivery of drug to the site of disease -- an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor, and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid will begin Phase 2 clinical study imminently. FX007, an intra-articular sustained release TrkA inhibitor is being developed to safely address the intractable pain associated with end stage osteoarthritis.
For more information please visit www.flexiontherapeutics.com.
SOURCE Flexion Therapeutics, Inc.